Risks
4 risks
Risk Intelligence
Middle East conflict impact on costs
View Risks →Ajanta Pharma Limited — Q4 FY26
Ajanta Pharma delivered a strong Q4 FY26 with revenue of INR 1,422 crore (+21% YoY) and PAT of INR 267 crore (+18% YoY), driven by stellar US generics growth (+56% YoY) and Africa branded generics (+37% YoY).
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma delivered a strong Q4 FY26 with revenue of INR 1,422 crore (+21% YoY) and PAT of INR 267 crore (+18% YoY), driven by stellar US generics growth (+56% YoY) and Africa branded generics (+37% YoY). The India business grew 9% in Q4, while Asia declined 10% due to Middle East supply chain disruptions. For FY27, management guides for high-teens revenue growth and EBITDA margin of ~27% (vs 26% in FY26), with US generics expected to moderate to mid-single-digit growth. Key risks include prolonged Middle East conflict impacting raw material and freight costs, and potential FDA action at the Paithan facility following a Form 483 with 5 observations.
अजंता फार्मा ने वित्त वर्ष 2026 की चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई 1,422 करोड़ रुपये रही, जो पिछले साल से 21% ज्यादा है। मुनाफा 267 करोड़ रुपये हुआ, जो 18% बढ़ा। यह अमेरिका में जेनेरिक दवाओं की बिक्री में 56% और अफ्रीका में ब्रांडेड जेनेरिक दवाओं में 37% की बढ़ोतरी से हुआ। भारत में कारोबार 9% बढ़ा, लेकिन एशिया में मिडिल ईस्ट की आपूर्ति में रुकावट के कारण 10% गिरावट आई। अगले वित्त वर्ष में कंपनी को 17-19% कमाई बढ़ने और मुनाफा मार्जिन 27% रहने की उम्मीद है। अमेरिका में जेनेरिक दवाओं की बिक्री धीमी होकर 5% तक बढ़ सकती है। जोखिमों में मिडिल ईस्ट संकट से कच्चे माल और ढुलाई की लागत बढ़ना, और पैठान फैक्ट्री पर एफडीए की कार्रवाई शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Generics Revenue (Q4)
INR 505 crore
+56% YoY
US generics delivered exceptional growth, contributing 29% of total revenue for FY26.
India Business Growth (FY26)
INR 1,654 crore
+14% YoY
India business outperformed IPM growth of 10%, with new products contributing 4.7% of growth.
Africa Branded Generics (Q4)
INR 182 crore
+37% YoY
Africa branded generics saw strong recovery, with 15% growth for the full year.
Asia Branded Generics (Q4)
INR 274 crore
-10% YoY
Asia business declined due to Middle East supply chain disruptions; management expects high double-digit growth in FY27.
What Changed vs Last Quarter
NEW
Revenue growth of high-teens for FY27
Management expects overall revenue growth in the high-teens range, driven by recovery in Asia and Africa, while US generics moderate.
NEW
EBITDA margin of ~27% for FY27
EBITDA margin guidance of 27% ±1%, factoring in investments in MR additions, R&D, and higher freight/raw material costs from Middle East conflict.
UPDATED
Capex of ~INR 400 crore for FY27
Capex includes INR 150 crore maintenance and INR 250 crore for capacity expansion at existing sites.
UPDATED
US generics mid-single-digit growth in FY27
US generics expected to grow at mid-single digits due to high base and seasonal flu product impact; 4-5 new launches planned in H2.
DROPPED
EBITDA margin guidance of 27%±1% for FY26
Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding mark-to-market forex impact.
DROPPED
Gross margin around 78%±1% for FY26
Gross margin expected to remain around 78%±1% for the full year.
NEW RISK
Middle East conflict impact on costs
Prolonged conflict could increase raw material and freight costs, which management expects to absorb for 2-3 months but may pressure margins beyond.
NEW RISK
US FDA Form 483 at Paithan facility
Five observations received; potential escalation could impact US filings or existing product supplies if not resolved satisfactorily.
NEW RISK
Promoter pledge increase
Pledge by two promoter brothers for unrelated businesses has risen; though management says it's not company-related, it could signal personal financial stress.
RISK GONE
Competition in GLP-1 market in India
Analyst raised concern about aggressive competition in India for GLP-1; management acknowledged 15-20+ competitors expected.
RISK GONE
Forex volatility impact on margins
Mark-to-market forex loss of INR 61 crore in 9M impacted EBITDA margin; management excluded it from guidance but risk remains.
RISK GONE
Execution risk in new geographies and M&A
Management mentioned potential entry into Latin America and active M&A pipeline; execution and integration risks are high.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY25
The Africa institutional segment declined 53% in Q4 and remains unpredictable due to donor funding uncertainties, including potential USAID cuts.
Mentioned in Q1 FY26, Q2 FY26
Africa business guidance upgraded from mid-single-digit to double-digit growth for the full year.
Mentioned in Q1 FY26, Q2 FY26
Mark-to-market forex losses of INR 41 crore in Q2 distorted EBITDA margin; continued volatility could mask underlying performance.
Mentioned in Q1 FY25, Q4 FY25
Management expects to file 10-12 ANDAs in FY26, with a robust pipeline and several products in advanced stages.
Mentioned in Q2 FY25, Q3 FY25
Entry into gynecology and nephrology in India and CNS in Asia will increase SG&A and personnel costs, potentially pressuring near-term margins.
Fast read
Guidance and risk preview
Management expects overall revenue growth in the high-teens range, driven by recovery in Asia and Africa, while US generics moderate.
Prolonged conflict could increase raw material and freight costs, which management expects to absorb for 2-3 months but may pressure margins beyond.
View Risks →